Product Expansion Leverage CMP Pharma’s track record of launching FDA-approved liquid oral formulations (e.g., Tadliq, Atorvaliq, Norliqva) to position for partnerships that expand a liquid dosage portfolio into other actives or labeling opportunities, especially where liquid formulations currently underrepresented.

Alcohol-Free Advantage Promote collaborations around alcohol-free reformulations for pediatric or sensitive patient populations, building on the recent Norliqva alcohol-free update to address markets seeking taste, safety, and compliance benefits.

Niche Liquid Expertise Target institutions and distributors prioritizing liquid suspension expertise for cardiovascular and diuretic therapies, capitalizing on CMP Pharma’s specialization in FDA-approved oral suspensions and unit-dose packaging to meet patient access needs.

Regional Growth Focus on expanding distribution and contract manufacturing opportunities in North Carolina and nearby states, leveraging CMP Pharma’s local footprint, growing product launches, and mid-market revenue potential.

Strategic Partnerships Explore co-branding, licensing, and co-development deals with larger pharma players seeking to augment their liquid formulation pipelines with CMP’s established capabilities and recent successful launches.